128 related articles for article (PubMed ID: 6141119)
1. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
[TBL] [Abstract][Full Text] [Related]
2. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
3. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
4. Effects of somatostatin infusion in four patients with malignant carcinoid syndrome.
Quatrini M; Basilisco G; Conte D; Bozzani A; Bardella MT; Bianchi PA
Am J Gastroenterol; 1983 Mar; 78(3):149-51. PubMed ID: 6187212
[TBL] [Abstract][Full Text] [Related]
5. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
6. [Effect of somatostatin and salmon calcitonin on carcinoid syndrome. A clinical case].
Festa V; Garrone C; Vietti Ramus G; Lisa F; Simone P; Scotti M; Cocchis D; Garrone GC
Minerva Chir; 1989 May; 44(9):1429-33. PubMed ID: 2569698
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
8. Histamine release from a gastric carcinoid: provocation by pentagastrin and inhibition by somatostatin.
Roberts LJ; Bloomgarden ZT; Marney SR; Rabin D; Oates JA
Gastroenterology; 1983 Feb; 84(2):272-5. PubMed ID: 6184258
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
Altman AR; Tschen JA; Rice L
Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites.
Matuchansky C; Launay JM
Gastroenterology; 1995 Mar; 108(3):743-51. PubMed ID: 7533112
[TBL] [Abstract][Full Text] [Related]
12. Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome.
Davis GR; Camp RC; Raskin P; Krejs GJ
Gastroenterology; 1980 Feb; 78(2):346-9. PubMed ID: 7350058
[TBL] [Abstract][Full Text] [Related]
13. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing features of idiopathic flushing and carcinoid syndrome.
Aldrich LB; Moattari AR; Vinik AI
Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
[TBL] [Abstract][Full Text] [Related]
15. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
16. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin does not prevent serotonin release and flushing during chemoembolization of carcinoid liver metastases.
Zimmer C; Kienbaum P; Wiesemes R; Peters J
Anesthesiology; 2003 Apr; 98(4):1007-11. PubMed ID: 12657865
[No Abstract] [Full Text] [Related]
18. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
19. [Anaesthetic management for hemihepatectomy in a patient with carcinoid-syndrome].
Zimmer C; Günnicker M; Peters J
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Dec; 36(12):763-7. PubMed ID: 11743674
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome.
Parris WC; Oates JA; Kambam J; Shmerling R; Sawyers JF
Can J Anaesth; 1988 Jul; 35(4):413-6. PubMed ID: 2900085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
